Pharmaceutical Executive-02-01-2010

Issue PDF
Pharmaceutical Executive

February 01, 2010

Shire’s Second Act

Pharmaceutical Executive
Features

February 01, 2010

As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.

Pharmaceutical Executive
Features

February 01, 2010

The British specialty shop was once a laughing stock. Now it’s one of pharma’s fastest growing mid-size firms, with a patent cliff bridged and a biotech engine of orphan drugs. So why does CEO Angus Russell fret that success might spoil Shire?

Pharmaceutical Executive
Columns

February 01, 2010

Improving field force business planning requires managers to run each sales territory as if it is a self-contained business operation.

Pharmaceutical Executive
Washington Report

February 01, 2010

R&D is surging, but new methods and data raise new manufacturing and regulatory challenges.

Pharmaceutical Executive
Features

February 01, 2010

Sales compensation practices are due for an overhaul in 2010.

Pharmaceutical Executive
From the Editor

February 01, 2010

Innovation won't happen until the industry is ready to sit down and make a big change.